What normally happens in the first 72 hours

Swelling, a dull ache, and stiffness in the first day or two after a ChondroFiller injection are expected — and they are signs the joint is responding normally, not that something has gone wrong.

Three reactions are typical in the first 72 hours:

• Localised swelling — usually most noticeable around the 24-hour mark, then gradually settling over the following day or two.
• A dull, pressure-like ache — distinctly different from sharp pain. The sensation reflects the joint accommodating the collagen scaffold; it should feel like mild pressure rather than acute discomfort.
• Joint stiffness — especially noticeable first thing in the morning or after sitting. This eases progressively as swelling reduces through the 48–72-hour window.

All three are physiological responses to scaffold placement inside the joint. The arc matters: symptoms peak around 24 hours, then follow a consistent downward trajectory. That improving trend is itself reassuring.

Light walking is appropriate from the outset — gentle movement encourages circulation and is not harmful to the scaffold. Activity restrictions in the days and weeks that follow are covered in the recovery guidance section.

What the safety record actually shows

Across more than 19,000 treated cases compiled since ChondroFiller entered clinical use in 2013 — the largest directly relevant dataset for this procedure — no serious adverse device effects (SADEs) have been reported. The overall complaint rate across that post-market surveillance record sits at approximately 0.06%, with the device-related complication rate described as negligible in the manufacturer's Clinical Evaluation Report (CER Version 09, April 2025).

Clinical studies report a complication rate of approximately 0%. For context: microfracture, the most common surgical cartilage procedure, carries a reported complication rate of 0–7%, while cell-based approaches such as ACI and MACI reach up to 17%. On reoperation, ChondroFiller's rate of approximately 3–8% compares with figures of around 37–41% for those surgical alternatives. Taken together, these numbers suggest ChondroFiller's complication profile sits at the lower end of cartilage-repair options currently in clinical use.

Independent corroboration comes from a 2025 prospective study by Matta et al. (PubMed Central) examining ChondroFiller use in wrist cartilage repair, which found no significant difference in complications between treated patients and controls — lending external weight to figures that otherwise come primarily from manufacturer-sponsored surveillance.

One caveat applies throughout: post-market safety data reflects patients carefully matched to the procedure beforehand — well-contained defects, stable joint mechanics, no absolute contraindications. These figures do not generalise to every joint-pain presentation, and individual suitability always requires clinical assessment.

Why the acellular design keeps immune risk low

The reason the safety profile looks as it does comes down to what ChondroFiller does not contain: donor cells.

Cell-based cartilage therapies such as ACI and MACI introduce living cells into the joint — and wherever foreign cells are present, the immune system has material to react against. ChondroFiller is acellular: it is a purified Type I collagen matrix with no donor or foreign cells at all. Without those cellular signals, the immune system faces none of the rejection triggers that cell-based repair techniques carry.

What the scaffold does instead is act as a recruitment structure. Once placed in the defect, it draws the patient's own progenitor cells — from the surrounding synovium and the underlying subchondral bone — into the repair site. The resulting tissue repair is autologous in practice, even though the scaffold itself originates externally. This process is described clinically as acellular matrix-induced chondrogenesis.

One nuance worth noting: ChondroFiller is derived from murine (rat) Type I collagen. That origin is relevant to hypersensitivity risk — which is why pre-treatment screening is required — but it does not produce the cellular rejection responses associated with donor-cell therapies. The two risks are mechanistically distinct.

Red flags: reactions that need prompt attention

Knowing when to act — and when not to — comes down to one simple rule: direction of travel.

Normal recovery moves in one direction only: gradual improvement. Swelling reduces, the ache softens, stiffness eases. That trajectory should be well established by 72 hours. Infection does the opposite. Where normal recovery is a downward slope, infection reverses the curve — and it is that reversal, not any single symptom on its own, that warrants prompt contact with the treating clinic.

Infection warning signs

The pattern to watch for after the 72-hour mark:

• Escalating warmth around the joint, rather than warmth that is slowly abating
• Spreading redness at or beyond the injection site
• Swelling that continues to build rather than gradually settling
• Systemic fever — often the clearest signal that something more than local inflammation is happening

No single item on that list is definitive in isolation. It is the trend — worsening across multiple signals simultaneously — that distinguishes a post-procedure complication from ordinary recovery discomfort.

Collagen hypersensitivity

A separate and distinct risk involves the collagen itself. As noted, ChondroFiller is derived from murine (rat) Type I collagen, which is why pre-treatment allergy screening is standard practice. Hypersensitivity to the material is uncommon, but it is an absolute contraindication — meaning the injection should not go ahead if it is confirmed.

Anyone with a known or suspected sensitivity to animal-derived collagen, or to rat proteins specifically, should disclose this clearly before any appointment. If a hypersensitivity reaction occurs after treatment, the response is different from the infection pathway: contact the treating clinic promptly, and do not proceed with any further injections in the same series without clinical review.

These two risks — infection and hypersensitivity — call for different responses, and it is worth keeping them separate mentally. Both are uncommon; both are manageable when identified early.

Contraindications and who is not a suitable candidate

Several conditions make ChondroFiller unsuitable regardless of how well-contained a cartilage defect appears. Each applies for a mechanistic reason, not as an arbitrary restriction.

• Confirmed hypersensitivity to murine (rat-derived) collagen — as discussed, screening is standard practice before treatment because a hypersensitivity reaction cannot be managed with technique adjustments alone; it rules the procedure out.
• Active joint infection — introducing a scaffold into an infected joint would provide an additional surface for bacterial colonisation. Any active infection must be fully resolved before an intra-articular injection proceeds.
• Bleeding disorders or anticoagulant therapy that cannot be safely paused — intra-articular injection carries a small risk of haemarthrosis (bleeding into the joint), a risk that is meaningfully heightened when clotting is impaired.
• Active malignancy — a contraindication common to most regenerative procedures; a pro-regenerative scaffold environment should not be created in the presence of active cancer.
• Kellgren-Lawrence Grade IV osteoarthritis — the Kellgren-Lawrence (KL) scale grades joint degeneration from I to IV on imaging, with Grade IV representing bone-on-bone contact. At that stage, cartilage loss is too advanced and too widespread for a focal scaffold to address. ChondroFiller is designed for contained defects within a joint that retains workable overall mechanics; it is not a treatment for end-stage, global degeneration.

The clinical consultation is the appropriate place to assess all of these factors. Its purpose is to determine whether ChondroFiller is genuinely suitable for a particular patient — not to ratify a decision already made. If a contraindication is identified, the assessment will indicate a more appropriate pathway instead.

Aftercare, rare complications, and the next step

The immediate gelation window is only part of the aftercare picture. Weight-bearing restrictions over the first few weeks matter for a mechanically distinct reason: before the patient's own progenitor cells migrate into the scaffold and begin integrating, the matrix is vulnerable to physical disruption. Loading the joint too aggressively during this period risks dislodging a structure that has not yet had time to bond with surrounding tissue. The treating clinician will specify the protocol based on joint and defect location; the principle behind it is progenitor cell integration, not arbitrary rest.

Two rare technical complications

Two further complications arise from procedural factors rather than patient biology. Neither is common, but both belong in a complete account of the risk picture.

Fibrous tissue formation can follow overfilling — when scaffold is placed proud of, rather than flush with, the defect surface, abnormal tissue may form at that protrusion. Precise image-guided placement is the direct safeguard; it is one practical reason ultrasound guidance is standard for this injection pathway.

Non-gelation — failure of the collagen matrix to polymerise and set inside the defect — is estimated at approximately 0.01% of cases. At that frequency it is more a described possibility than a recurring clinical pattern, but it is part of the honest risk picture.

What this means for candidacy

These technical considerations reinforce why patient selection and accurate defect characterisation matter before the injection proceeds. The safety figures described earlier in this article reflect procedures carried out in appropriately selected patients; the same outcomes cannot be assumed where joint mechanics or defect geometry fall outside those criteria. A specialist cartilage assessment — covering imaging, defect size, load-bearing mechanics, and the contraindications discussed above — is the appropriate first step for anyone considering this pathway. Specialist assessment is available via londoncartilage.com.